source
- INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCCFirst-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.onclive · 2mo ago↗ source
- Treatment Intensification Gains Momentum in mCSPC ManagementDuring a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.onclive · 2mo ago↗ source
- STAT+: Astellas treatment offers new hope to a devastated rare disease communityAlzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The ReadoutSTAT · 2mo ago↗ source